EUVIMEDEUVIMED entdecken
Open Access

Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy

Jonathan Douxfils, Jean-Michel Foidart, Ulysse Gaspard, Guillaume Chatel, Mélanie Taziaux, Maud Jost, Céline Gérard, Laure Morimont

Menopausal Review · 2023 · 22 (2) · 117-119

DOI: 10.5114/pm.2023.128815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Menopausal Review, 2023. Verfasst von Jonathan Douxfils und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AMA Douxfils J, Foidart J, Gaspard U, et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815. APA Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M., & Jost, M. et al. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), 117-119. https://doi.org/10.5114/pm.2023.128815 Chicago Douxfils, Jonathan, Jean-Michel Foidart, Ulysse Gaspard, Guillaume Chatel, Mélanie Taziaux, Maud Jost, and Céline Gérard et al. 2023. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy". Menopause Review/Przegląd Menopauzalny 22 (2): 117-119. doi:10.5114/pm.2023.128815. Harvard Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M., Jost, M., Gérard, C., and Morimont, L. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), pp.117-119. https://doi.org/10.5114/pm.2023.128815 MLA Douxfils, Jonathan et al. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy." Menopause Review/Przegląd Menopauzalny, vol. 22, no. 2, 2023, pp. 117-119. doi:10.5114/pm.2023.128815. Vancouver Douxfils J, Foidart J, Gaspard U, Chatel G, Taziaux M, Jost M et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815.

Autor:innen und Institutionen

  • Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.
  • Department of Gynecology, University of Liège, Liège, Belgium.
  • Mithra Pharmaceuticals, Liège, Belgium.

Zitieren

APA

Douxfils, J., Foidart, J. M., Gaspard, U., Chatel, G., Taziaux, M., Jost, M., Gérard, C., & Morimont, L. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopausal Review, 22(2), 117-119. https://doi.org/10.5114/pm.2023.128815

Vancouver

Douxfils J, Foidart JM, Gaspard U, Chatel G, Taziaux M, Jost M, et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopausal Review. 2023;22(2):117-119. doi:10.5114/pm.2023.128815

BibTeX
@article{Douxfils2023,
  author = {Douxfils, Jonathan and Foidart, Jean-Michel and Gaspard, Ulysse and Chatel, Guillaume and Taziaux, Mélanie and Jost, Maud and Gérard, Céline and Morimont, Laure},
  title = {Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy},
  journal = {Menopausal Review},
  year = {2023},
  volume = {22},
  number = {2},
  pages = {117--119},
  doi = {10.5114/pm.2023.128815}
}
Kostenlos starten →